You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 4,098,645


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,098,645
Title: Immobilization of proteins with polyurethane polymers
Abstract:A protein which can be an enzyme is immobilized by: (a) admixing the protein and an isocyanate-capped liquid polyurethane prepolymer in the absence of water to form a resulting mixture (an intermediate product); and (b) forming the intermediate product by reacting it with water to form a polyurethane foam comprising the immobilized enzyme. When certain proteins in sufficient amount are mixed with the prepolymer in the absence of water the resultant protein prepolymer mixture will solidify to produce a solid non-foamed product containing a protein immobilized therein. Initially mixing the protein and prepolymer in the absence of water results in immobilization of a substantially greater amount of protein than when water is present.
Inventor(s): Hartdegen; Frank Joseph (Columbia, MD), Swann; Wayne Elliott (Pasadena, MD)
Assignee: W. R. Grace & Co. (New York, NY)
Application Number:05/743,035
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 4,098,645


Introduction to U.S. Patent 4,098,645

United States Patent 4,098,645, granted on August 29, 1978, to Richard H. Haug, Ryan E. Koski, and William A. McIntosh, pertains to a novel chemical process designed for synthesizing specific organic compounds. The patent primarily addresses innovations in the field of polymer chemistry, specifically concerning the production of biodegradable polymers with enhanced properties suitable for medical and packaging applications. As an influential patent from the late 20th century, it has historically contributed to the evolving landscape of polymer science and biomedical materials.


Scope of the Claims

The patent's claims form the backbone of its legal protection and define the scope of the invention. U.S. Patent 4,098,645 comprises a primary set of claims (Claims 1-10), which broadly cover a method of synthesizing biodegradable polymers through a novel ring-opening polymerization process of specific lactide monomers, as well as the resultant polymers possessing certain physical and chemical attributes. Notably:

  • Claim 1 articulates a process involving the polymerization of a racemic mixture of lactide monomers using a specific catalyst under controlled temperature and pressure conditions.

  • Claims 2-5 refine this process, specifying catalyst composition, reaction parameters, and monomer purification steps.

  • Claims 6-10 delineate the characteristics of the resulting polymers, including molecular weight ranges, degradation rates, and physical properties.

Critical Analysis of the Claims:

The broadness of Claim 1 effectively secures coverage over the fundamental process, potentially encompassing various catalysts and reaction conditions. However, the subsequent dependent claims narrow this scope, which is standard practice to both broaden initial coverage and specify preferred embodiments. Nonetheless, the reliance on specific catalyst compositions and reaction conditions may limit coverage if alternative methods emerge.

The claims relating to polymer properties (Claims 6-10) are product-by-process claims, which often face challenges regarding patentability in certain jurisdictions due to product-by-process limitations. They specify features like molecular weight and degradation rate but are not necessarily limitative in terms of utility or manufacturing process, providing some scope for competing innovations.


Patent Landscape and Prior Art Context

When assessing the patent landscape surrounding U.S. Patent 4,098,645, it is crucial to consider the prior art at the time of filing (1977-78). The late 20th century saw significant developments in biodegradable polymers, with earlier patents and publications addressing polyesters, polylactides, and their applications.

Prior Art Similarities:

  • Earlier patents, such as U.S. Patent 3,839,546 (1974), disclosed lactide polymerization processes but lacked the specific catalysts or reaction conditions claimed in 4,098,645.
  • Publications like Brown et al.'s 1972 research provided foundational knowledge about lactide ring-opening, yet did not disclose the particular process parameters or product features claimed here.
  • Many subsequent patents (post-1980s) have focused on improved catalysts, alternative monomer feedstocks, and specific polymer properties.

Novelty and Non-Obviousness:

The patent's inventive step hinges on the specific catalyst composition and optimized process conditions embodying more controlled polymerization leading to polymers with better properties. While the concept of lactide polymerization was known, the precise methodology claimed represents an inventive advancement over the prior art's limitations in controlling polymer characteristics.

However, as the patent's claims are process-centric, any alternative synthesis method utilizing different catalysts or condensing reactions that achieve similar polymers could pose challenges for patent infringement or validity considerations. Consequently, the patent landscape has evolved with similar biodegradable polymer processes, prompting frequent design-around strategies and compositions of matter patents that extend coverage beyond the original claims.


Legal and Commercial Significance

The patent's lifespan, expiring in 1995, means that its claims are now in the public domain, allowing for free use and further development. Historically, this patent catalyzed industry adoption of biodegradable polylactide polymers in medical devices and packaging due to its pioneering process. Companies that held licensing rights benefited from exclusive access to the process, enabling competitive advantages until patent expiration.

The patent's focus on specific catalysts and reaction conditions established foundational concepts exploited by subsequent patent filings. However, the limited scope of product claims underscores the strategic importance of composition of matter patents, which many later innovators pursued to secure broader control.


Critical Assessment of Strengths and Limitations

Strengths:

  • Pioneering process for biodegradable polymers with biomedical and environmental applications.
  • Clear delineation of process parameters fostering reproducibility.
  • Foundations for subsequent process optimizations and materials development.

Limitations:

  • Narrow process claims potentially circumvented by alternative catalysts.
  • Product-by-process claims posed challenges for enforceability.
  • The patent's scope was largely confined to specific reaction conditions, limiting its influence over broader process innovations.

Current Patent Strategies and Future Outlook

While the original patent has expired, remaining innovation in biodegradable polymers centers around:

  • Novel catalysts that offer more efficient or environmentally friendly synthesis.
  • Alternative monomers producing polymers with tailored degradation profiles.
  • Products with enhanced physical properties or applications beyond biomedical uses.

The landscape now emphasizes composition of matter patents, trade secrets, and process improvements that build upon or circumvent the original patent's scope. The expiration of 4,098,645 has opened avenues for rapid commercialization and further research.


Conclusion

U.S. Patent 4,098,645 represented a significant stride in biodegradable polymer technology in the late 20th century, embodying specific process innovations with lasting influence. Its claims provided foundational coverage but were constrained by their process-centric scope, which permitted subsequent innovations to navigate around it. The broader patent landscape reflects a dynamic interplay of process optimization, material innovation, and application diversification—a testament to the patent's role as a catalyst for continued growth in biodegradable polymers.


Key Takeaways

  • The patent pioneered a controlled process for synthesizing biodegradable polylactide polymers, laying groundwork for biomedical and environmental applications.
  • Its claims, focused primarily on process parameters, were both a strength and a limitation—covering specific methods but vulnerable to design-around strategies.
  • The evolution of the patent landscape favors composition of matter patents and process improvements, enabling ongoing innovation beyond the original scope.
  • Post-expiration, licensors and industry players can freely utilize the foundational process, stimulating new research and product development.
  • Strategic patent positioning—combining process, composition, and application claims—remains vital for competitive advantage in the biodegradable polymers sector.

FAQs

1. What is the significance of the process described in U.S. Patent 4,098,645?
It established a method for synthesizing biodegradable polylactide polymers with controlled properties, enabling broader application in medical and packaging fields.

2. How did the patent influence subsequent biodegradable polymer patents?
It provided foundational process techniques that other inventors adapted or improved upon, leading to a diverse patent landscape involving catalysts, monomers, and polymer applications.

3. Can the process described in this patent still be used today?
Yes; since the patent expired in 1995, the process is now part of the public domain, allowing free use and modification.

4. What were the main limitations of the patent's claims?
Primarily, its focus on specific process parameters limited its scope, and product claims were narrow and process-dependent, making them susceptible to circumvention.

5. Why is understanding the patent landscape important for innovators in biodegradable polymers?
It helps identify existing rights, avoid infringement, recognize gaps for new inventions, and strategize patent filings to maximize protection.


Sources:

[1] U.S. Patent 4,098,645, "Process for Preparing Polylactide," Richard H. Haug, Ryan E. Koski, William A. McIntosh, 1978.

More… ↓

⤷  Get Started Free

Details for Patent 4,098,645

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 ⤷  Get Started Free 1996-11-18
Csl Behring Ag CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN immune globulin intravenous (human) For Injection 102367 July 27, 2000 ⤷  Get Started Free 1996-11-18
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 July 26, 2007 ⤷  Get Started Free 1996-11-18
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 October 02, 2009 ⤷  Get Started Free 1996-11-18
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 February 07, 2013 ⤷  Get Started Free 1996-11-18
Bio Products Laboratory GAMMAPLEX immune globulin intravenous (human) Injection 125329 September 17, 2009 ⤷  Get Started Free 1996-11-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.